Your Daily Pharma Scoop: Esperion Phase 3 Positive, FDA Rejects Volanesorsen, Ozempic Succeeds [Seeking Alpha]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Seeking Alpha
Summary Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperion’s ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1002-053 ) has been reported by the company. This trial was conducted in a 380 high-risk patient group with maximally tolerated statins. The trial evaluated the efficacy and safety of the bempedoic acid 180 mg/ezetimibe 10 mg combination pill compared to bempedoic acid, ezetimibe or placebo. The trial met its key efficacy endpoint. The combination therapy reduced LDL-C at 12 weeks by 35%, and this clearly shows up against 3% reduction for placebo. The trial drug also clearly scores over 24% reduction shown by ezetimibe 10 mg (EZE) and 20% reduction shown by bempedoic acid 180 mg (BA). The fixed dose combination also showed a 34% reduction in high-sensitivity C-reactive protein (hsCRP)
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Publishes 2023 Corporate Responsibility Report [Yahoo! Finance]Yahoo! Finance
- Ionis Publishes 2023 Corporate Responsibility ReportPR Newswire
- n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
- Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- IONS's page on the SEC website